



## **Invitrocue Appoints Professor Ariel Zeng Yi as Patient Derived Organoid Consultant**

**February 18, 2019** – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Ariel Zeng Yi as Patient Derived Organoid (PDO) Consultant.

Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). She is an expert in the study of mammary stem cell and breast cancer for the purposes of regenerative and cancer medicine. Prof. Zeng holds a postdoctoral degree in Developmental Biology from Stanford University. She has authored and co-authored various research papers on mammary development, multipotent mammary stem cells and breast cancer.

Professor Zeng is currently spearheading Invitrocue's collaboration with the SIBCB to propagate and expand PDOs from breast cancer patients with multiple breast cancer subtypes, including *ER+*, *PR+*, *HER2+* and *TNBC*. Her work with the company will enable Invitrocue to optimise the testing protocols for breast cancer models and expedite the expansion of its Onco-PDO™ cancer indication menu for Invitrocue's proprietary Onco-PDO™ test.

As a consultant to Invitrocue, Prof. Zeng will also provide insights on breast cancer and oncology treatments as the company seeks to continue to broaden the applicability of the Onco-PDO™ personalised screening test.

### **Commenting on the appointment of Prof. Zeng, Dr. Steven Fang, Executive Chairman, Invitrocue, said:**

*"We are delighted to welcome Professor Ariel Zeng to Invitrocue as a consultant. Her research into organoids, specifically in breast cancer, is world-leading and will be of great benefit to Invitrocue as we focus on broadening the indication menu of Onco-PDO™. Working closely with our advisors and consultants like Professor Zeng, we are also continually broadening our network to educate key opinion leaders on the role of Onco-PDO™ as a key tool in evidence-based decision making for cancer treatments."*

**-END-**

### **For more information contact:**

Martin D. Bach, VP Operations

T: +65 6460 0497

[martind.bach@invitrocue.com](mailto:martind.bach@invitrocue.com)

**About Invitrocue**

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue's Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A\*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: [www.invitrocue.com](http://www.invitrocue.com)